(Q54025987)

23 May 2018

title

Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. (English)

1 reference

23 May 2018

main subject

arterial hypertension

0 references

pulmonary hypertension

1 reference

1

1 reference

23 May 2018

author name string

Warner JJ

2

1 reference

23 May 2018

Wang A

3

1 reference

23 May 2018

Harrison JK

4

1 reference

23 May 2018

Tapson VF

5

1 reference

23 May 2018

Bashore TM

6

1 reference

23 May 2018

language of work or name

English

0 references

publication date

1 December 2000

1 reference

23 May 2018

Journal of the American College of Cardiology

published in

1 reference

23 May 2018

volume

36

1 reference

23 May 2018

issue

7

1 reference

23 May 2018

page(s)

2204-2211

1 reference

23 May 2018

Primary pulmonary hypertension

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The management of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Chronic cor pulmonale. Etiology and management

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Combination of inhaled nitric oxide with i.v. nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Effects of inhaled nitric oxide in rats with chemically induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Low-dose inhaled nitric oxide for neonates with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Primary pulmonary hypertension. A national prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Delivery and monitoring of inhaled nitric oxide in patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The use of inhaled nitric oxide in a wide variety of clinical problems

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Role of endothelium-derived nitric oxide in the regulation of blood pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Long-term inhalation of nitric oxide for a patient with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Effect of inhaled nitric oxide on gas exchange in patients with congestive heart failure. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The effect of low-dose inhalation of nitric oxide in patients with pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Effect of inhaled nitric oxide on hemodynamics and VA/Q inequalities in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide in chronic obstructive lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide for the adult respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome. Effects on pulmonary hemodynamics and oxygenation.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide in congenital heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide and pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Long-term therapy for pulmonary hypertension in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nitric oxide in adult lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Role of vasoactive mediators in primary and secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The medical treatment of primary pulmonary hypertension. Proven and promising strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Nebulized prostacyclin for pulmonary hypertension: a step in the right direction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Long-term effects of nitrendipine on hemodynamics and oxygen transport in patients with cor pulmonale.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Felodipine improves pulmonary hemodynamics in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

The effect of the calcium antagonist, isradipine, on working capacity, pulmonary function, morbidity and survival rate in patients with severe chronic obstructive pulmonary disease (COPD): a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2800%2900994-3

7 January 2021

10.1016/S0735-1097(00)00994-3

Identifiers

DOI

1 reference

23 May 2018

1 reference

23 May 2018